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Salivarian trypanosomes are extracellular parasites that affect humans, livestock, and
game animals around the world. Through co-evolution with the mammalian immune
system, trypanosomes have developed defense mechanisms that allow them to thrive
in blood, lymphoid vessels, and tissue environments such as the brain, the fat tissue,
and testes. Trypanosomes have developed ways to circumvent antibody-mediated killing
and block the activation of the lytic arm of the complement pathway. Hence, this makes
the innate immune control of the infection a crucial part of the host-parasite interaction,
determining infection susceptibility, and parasitemia control. Indeed, trypanosomes use
a combination of several independent mechanisms to avoid clearance by the humoral
immune system. First, perpetuated antigenic variation of the surface coat allows to
escape antibody-mediated elimination. Secondly, when antibodies bind to the coat, they
are efficiently transported toward the endocytosis pathway, where they are removed
from the coat proteins. Finally, trypanosomes engage in the active destruction of the
mammalian humoral immune response. This provides themwith a rescue solution in case
antigenic variation does not confer total immunological invisibility. Both antigenic variation
and B cell destruction pose significant hurdles for the development of anti-trypanosome
vaccine strategies. However, developing total immune escape capacity and unlimited
growth capabilities within a mammalian host is not beneficial for any parasite, as
it will result in the accelerated death of the host itself. Hence, trypanosomes have
acquired a system of quorum sensing that results in density-dependent population
growth arrest in order to prevent overpopulating the host. The same system could
possibly sense the infection-associated host tissue damage resulting from inflammatory
innate immune responses, in which case the quorum sensing serves to prevent excessive
immunopathology and as such also promotes host survival. In order to put these
concepts together, this review summarizes current knowledge on the interaction between
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trypanosomes and the mammalian innate immune system, the mechanisms involved in
population growth regulation, antigenic variation and the immuno-destructive effect of
trypanosomes on the humoral immune system. Vaccine trials and a discussion on the
role of innate immune modulation in these trials are discussed at the end.
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INTRODUCTION
Human African Trypanosomosis (HAT) and Animal
Trypanosomosis (AT) are parasitic diseases that are caused
by unicellular protozoan organisms of the class Kinetoplastida.
While classic HAT is a disease that is strictly confined to
specific areas of sub-Sahara Africa, AT is a disease that is
found on all continents except Antarctica. Most pathogenic
livestock trypanosomes are salivarian trypanosome that are
being transmitted by the bite of a bloodsucking vector. Often,
transmission is the result of insect bites, but mechanical incidents
such as vampire bat bites or injury-induced blood contact can
also be a source of disease transmission. Human trypanosome
infections are in 98% of all cases the consequence of the
Trypanosoma (Trypanozoon) brucei gambiense parasite that
occurs in West- and Central-Africa. The remaining infections
are caused by zoonotic Trypanosoma brucei rhodesiense parasites.
HAT is geographically restricted to sub-Sahara Africa as T. brucei
parasites strictly depend on completion of their lifecycle inside
their final host, i.e., the tsetse (Glossinidae) fly. Occasional HT
infections have been reported outside Africa. These cases are
classified as non-classic Human Trypanosomosis and are the
result of Trypanosoma (Trypanozoon) evansi infections. So far,
such infections have only been reported in Asia, even though the
causative agent is also present in South America, Africa, northern
islands of Oceania and even occasionally occurs in Europe. In
contrast to HAT, animal trypanosomosis is caused by a wide
range of trypanosomes. To start, T. evansi is the most widely
distributed animal trypanosome. This is a consequence of the
fact that the parasite has a very wide transmission vector range
combined with a very wide mammalian host range. It has evolved
beyond the need to complete its lifecycle inside the tsetse fly and
hence has been able to move away from the sub-Saharan tsetse
belt. Secondly, Trypanosoma (Dutonella) vivax is a livestock
parasite that is found in sub-Sahara Africa and South America.
Also here, the transmission vector range extends beyond
the insect reservoir, as additional mechanical transmission
modalities contribute to disease spread. Thirdly, Trypanosoma
(Nannomonas) congolense is restricted to the African continent.
This parasite is mainly transmitted by blood sucking insects
from the families of Glossinidae, Tabanidae, Chrysops, Atylotus,
and Muscidae. The host tropism for this parasite ranges from
domestic animals with economic importance, to wildlife species
that harbor parasites as a reservoir, without suffering from severe
infection-associated pathology. The latter makes it virtually
impossible to envisage the total eradication of this parasite from
the African continent. Finally, Trypanosoma (Trypanozoon)
brucei is considered a vector transmitted parasite with veterinary
importance, although the “disease” contribution of this parasite
to the overall problem of trypanosomosis is minor. Besides
the vector borne trypanosomes, there is also Trypanosoma
(Trypanozoon) equiperdum, which is a sexually transmitted
parasite that causes a deadly disease in equines. Over the years
this parasite has occasionally caused havoc in Southern Europe
due to illegal or ill-controlled import of infected livestock. The
geographic distribution of all HAT and AT causing parasites
and general aspects of the immunopathology related to their
infections were recently reviewed by Radwanska et al. (1).
In general, host immune responses and immune evasion
strategies of salivarian trypanosomes are comparable, although
specific host-parasite interactions do govern unique aspect
of infection depending upon both parasite and host species.
The general hallmarks of infections can be considered to be
(i) activation of the innate immune system helping initial
parasitemia control, but also driving immune pathology, (ii)
antigenic variation of the parasite attempting the evasion of the
antibody immune response, and (iii) modulation and destruction
of the adaptive immune system (2). In addition, there is the
strict regulation of parasite proliferation in the mammalian host
that contributes to the intricate control of the host-parasite
interaction, as well as the tissue tropism that contributes to
the specific characteristics of disease outcome (3). This includes
the density-dependent differentiation from the proliferative
bloodstream form into the non-proliferating parasite form that
is adapted to transmission to the insect vector. In case of HAT,
there are two extra components that add to this equation. The
first is that during chronic infection, parasites cross the blood
brain barrier where they can hide from most of the immune
system, causing the deadly neurological pathology outcome of
sleeping sickness. The second component is the presence of
lytic factors in human serum. These offer protection against
all trypanosomes except T. b. gambiense, T. b. rhodesiense and
possibly some isolates ofT. evansi, which have acquired resistance
mechanisms that defeat the lytic human serum activity. While
some consider these lytic factors to be part of the humane
innate immune system, the biochemical trypanolytic activity
of human serum factors should probably more adequately be
described as a secondarymoonlighting effect of the serum protein
APOL1, rather than an immune function sensu stricto. All these
interactions will be further discussed in this review.
With HAT being a zoonotic infection, control of human
infection by itself can result in the temporary reduction of
victim numbers, but in order to sustain disease control efforts,
the animal reservoir component needs to be considered as
well. That means that a sub-Saharan landmass of about 10
million km2, encompassing 36 countries, where trypanosomes
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and their transmission vectors are present, should not be
considered trypanosomosis-free until the entire livestock herd
as well as the wildlife game reservoir is cleared from infections.
This is obviously an impossible task to achieve. Hence, for
now, disease control relies on detection and treatment of
positively diagnosed HAT and AT cases, mass-treatment of
economically important animals, and efforts to control insect
vectors. Under these conditions, access to a protective anti-
trypanosome vaccine would be a huge advantage, and since
the 1970’s efforts have been undertaken to try and deliver such
intervention strategy. Unfortunately, nearly 50 years later, not a
single vaccine candidate has made it through a successful field
trial. All published efforts undertaken in this context, as well
as possible explanations of pitfalls of the applied protocols will
be discussed in this review. In short, most vaccine efforts have
been focusing on identifying antigens and protocols with a good
antibody-induction potential, being driven by the idea that B cell
mediated antibody production should be the ultimate weapon
against extracellular trypanosomes. However, this strategy does
not take into account two issues. The first is that that antibody
induction upon antigen stimulation, and B cell memory recall
potential during the initiation of infection, are two different
immunological concepts. It is the latter mechanism that fails
during trypanosomosis. Secondly, trypanosomes have acquired
a range of tools to avoid the dangers posed by antibodies as
they have adopted to survive in the confined environment of
the host blood. This is not a hostile environment, this is where
they “live.” One way to possibly circumvent these issues is to
focus on T cell epitope vaccination rather than B cell epitope
targeting (4). Indeed, while the latter is “anticipated” by the
parasite and has driven the evolutionary development, triggering
T cell memory prior to infection might be a way to boost the
immunological “help” in a way that so far has not been part of
the immunological pressure that drives the trypanosome genetic
drift. T cell vaccination would indeed speed up the initiation
of B cell help as well as activate innate inflammatory anti-
trypanosome responses upon initial parasite encounter. This
idea is based on the fact that trypanosome surface proteins
harbor several more conserved hidden epitopes that are not truly
immunogenic as such. However, once presented in an MHC-II
context by B cells to vaccine induced Th cells, these epitopes
could function as the kick-start intermediate link that could
tip the balance in favor of the host. Aspects of vaccine failure,
vaccine interference by trypanosomes, and ideas dealing with T
cell vaccination are being addressed later-on in this review.
TRYPANOSOME GROWTH AND REDUCE
PARASITE FITNESS IS CONTROLLED BY
INNATE IMMUNE RESPONSES
Sterile immunity against mammalian trypanosomosis never
seems to occur, especially not in murine model for salivarian
trypanosomosis. The term “resistance” that is often used to
describe for example C57BL/6 mice that show a relatively good
early parasite load control, and prolonged control of infection,
refers only to parasitemia control itself. It does not cover the
fact that these mice suffer from severe immunopathology, neither
does the term cover the fact that all trypanosome infected
C57BL/6 mice will succumb to infection. Similarly, “susceptible”
mice such as BALB/c mice, have increased levels of peak
parasitemia, often accompanied by a shorter survival time, but
exhibit signs of reduced inflammatory pathology as compared
to the more resistant strains. It is here that the innate response
against infections functions as a double edge sword. While an
early IFNγ-mediated inflammatory response will help to control
the onset of parasitemia as well as the height of peak parasitemia,
it will also be the source of infection-associated anemia, liver
inflammation, and the destruction of the adaptive immune
response. Hence, it needs to be counterbalanced by a later IL-10
response in order to avoid the occurrence of sever pathology. As
the aspects of trypanosomosis-associated immunopathology have
recently been reviewed elsewhere (5, 6) this review will rather
focus on the immune drivers able to trigger the innate responses
that help to control infection. When it comes to the latter, there
is a consensus about the fact that IFNγ is the key factor that
determines very early-on in infection, whether or not the host
will exhibit a relatively good level of parasitemia control (7). This
cytokine is first produced by NK cells (8), after which NKT and
T cells take over (9). This crucial role for IFNγ was first shown
by infecting C57BL/6 mice as well as IFNγ and IL-4 knock-out
mice (on the same genetic background) and demonstrating that
in the absence of IFNγ, mice became highly susceptible to T. b.
rhodesiense infection (7). This susceptible phenotype was directly
linked to the inability of macrophages to provide a proper anti-
VSG response in the absence of IFNγ activation, and their failure
to engage in the optimal pro-inflammatory response crucial for
the control of early-stage parasitemia (10). This early response
to trypanosomosis was shown to be MyD88 dependent (11)
and TLR9 dependent (12). Interestingly, exposure of susceptible
BALB/c mice to CpG ODN improved their relative resistance,
increased their pro-inflammatory cytokine production upon
trypanosome exposure and elevated anti-trypanosome B and T
cell responses, corroborating the importance of this pathway.
At the molecular level, the IFNγ stimulation of the macrophage
compartment offers an improved response to the recognition of
the trypanosome VSG-GPI anchor (13). The structure of this
anchor has been described in detail for both T. brucei (14)
and T. congolense (15) and was show to have a poly-mannose
carbohydrate unit that is at the core of the recognition by
macrophages. Recognition of this GPI glycosyl core by IFNγ
stimulated macrophages results in the induction of TNF, which
is the second cytokine that is key to the optimal control of an
early peak parasitemia. This was shown in both T. brucei (16)
and T. congolense (17) infections, using TNF knock-out mice
as well as treatment with anti-TNF neutralizing antibodies (18).
This TNF effect works in conjunction with nitric oxide (NO),
which was also demonstrated to be crucial for trypanosomosis
control. The role of NO by itself merits special mentioning here
as it is also involved in multiple aspects of trypanosomosis-
associated immunopathology. First, NO was shown to be the
main immunosuppressive macrophage product that suppresses
T cell mediate immunity and hence hampers the buildup of
T cell memory capacity early on in infection (19). NO is also
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able to exert a direct cytostatic activity on T. brucei (20) and
T. congolense (21). For the latter, differences in susceptibility
levels between mouse strains was directly linked to their NO
response during infection (22). In vivo antibody based killing
of trypanosomes also required the presence of IFNγ-mediated
NO production, most likely affecting parasite fitness during peak
parasitemia (23). Interestingly, also TNF has been suggested to
negatively affect parasite fitness, showing a direct trypanolytic
effect on some trypanosomes. However, for various trypanosome
stocks, this effect was not confirmed in the absence of other
inflammatory effector molecules such as NO. What does seem
to be a more universal observation is the fact that TNF signaling
during trypanosomosis is mainly mediated by the TNF receptor-
I (TNFp55) (17). As this receptor also drives the induction of
immunopathology, this signaling pathway itself can lead to a dual
outcome. Interestingly, hosts that respond to acute experimental
trypanosomosis by shedding of their soluble TNF receptor-
II (TNFp75) suffer much less infection-associated pathology
as this mechanism can serve as a two-stage scavenger/release
principle. Indeed, during acute TNF production, the presence of
the soluble p75 receptor causes the neutralization of the cytokine
by forming a receptor-target complex in the circulation. Once the
concentration of TNF starts to drop, the complex dissociates and
ensures the prolonged presence of the cytokine in the circulation,
helping the prolonged control of parasitemia (24).
Most knowledge covering natural and innate resistance to
trypanosomosis is derived from experimental mouse infections,
which often are initiated by the intra-peritoneal injection
of bloodstream form parasites. However, when intradermal
infections are initiated with such parasites, T. congolense as well
as T. brucei experiments have shown that the minimum dose
required to obtain infection is 100 times higher compared to
the dose required for initiation of infection by intraperitoneal
injection. This observation suggest that there are improved
innate anti-parasite response that govern surveillance at the
dermal exposure sites (25). These results could be relevant for
vector transmitted infections, as at least in cattle it was shown
that it is the innate arm of the immune system, and not the
hematopoietic system, that controls parasite growth (26). One
obvious cellular player than comes to mind when considering
dermal immunology is the presence of neutrophils. Surprisingly,
a recent study addressing the role of these innate cells during
the onset of infection has shown that they have an infection-
enhancing effect, rather than an inhibitory function (27). While
the functional role of these cells has not been addressed in other
immune sites, their cell number increases dramatically in the
spleen of trypanosome infected mice (28).
As for the innate control of human infection, the situation
is not totally clear. For a long time, HAT has been called a
“lethal” infection, but now the notion is being accepted that there
are individuals that carry long-lasting asymptomatic infections.
Here, blood parasite levels are so low they are impossible to
detect (29). Hence, it could be that a very efficient innate control
mechanism manages to subdue infection from the start and does
not allow the parasite ever to reach detectable levels in these
HAT cases. Till now, it is not clear which mechanisms exactly
would drive this resistance as very little HAT-tolerance data is
available.While IL-8 has been suggested to be a possible mediator
here, TNF and IL-10 have both been associated with disease
development (30). An IL-17/Th17 driven susceptibility pathway
that has been suggested to occur in T. congolense infections (31),
has so far not been corroborated to contribute to human HAT
related immunopathology or regulation of tolerance.
NON-IMMUNE “INNATE” PRIMATE SERUM
FACTORS CAN OFFER BIOCHEMICAL
PROTECTION AGAINST
TRYPANOSOMOSIS
While the innate immune system of the vertebrate host is a crucial
determinant during the onset of a trypanosomes infection, there
are additional components that will determine whether or not the
initiation of infection is successful. This relates to the fact that
the biochemical composition of certain vertebrate host plasma
simply does not allow particular parasites to grow. Indeed, while
T. b. gambiense and T. b. rhodesiense are considered severe
human pathogens, T. b. brucei parasite are unable to survive
in human blood due to the particular biochemical composition
of human serum. Hence, the latter poses no danger to human
health. The fact that the biochemical composition of host serum
can determine whether or not a given trypanosome species can
successfully initiate an infection, was first proposed when the
growth of T. b. brucei, T. b. gambiense, and T. b. rhodesiense were
analyzed in the presence of normal (non-immune) human serum
(NHS). The fact that T. b. brucei is lysed by NHS through an
immune-independent mechanism explained why this parasite is
unable to infect humans. This trypanolytic biochemical activity is
not just found in human serum, but is also present in the blood
of other nonhuman primates such as gorilla, baboon, mandrill
and sooty mangabey serum, but not chimpanzee, orangutan
and macaque (32). In human serum, two different trypanolytic
fractions have so far been identified, i.e., TLF1 and TLF2. While
both fractions are part of the high-density lipoprotein (HDL)
subfraction, they differ in some aspects of their composition,
with TLF2 containing a natural IgM fraction (33). What they
do have in common is that they contain two compounds that
are now generally been agreed upon as necessary for the lytic
activity, i.e., Apolipoproteins L1 (APOL1) as the actual lytic
compound, and haptoglobin-related protein (Hpr) needed for
receptor recognition. While some have called the TLFs as “novel
components of the innate immunity” (34), one might argue that
they are actually not true immune actors and that the trypanolytic
activity of these HDL fractions are biochemical activities that
support protection against certain trypanosome species due
to a fortunate moonlighting function. Within the context of
this review, it is however interesting to highlight the defense
principles that TLFs offer against trypanosomes, and how both
T. b. rhodesiense and T. b. gambiense have acquired individual
mutations that in turn offers protection against TLFs. First, the
primary discovery of howT. b. rhodesiense is able to grow inNHS,
while T. b. brucei is not, started in the 1980s with a long-term
genetic analysis project comparing different T. b. rhodesiense
stocks with various levels of NHS resistance and T. b. brucei
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stocks. This work culminated in the discovery of SRA (serum
resistance antigen), a homolog of the variant surface glycoprotein
(VSG) that makes up for the bulk of the trypanosomes surface
coat and is crucial for protection against antibody-mediated
immune attacks. SRA is constitutively expressed by all T. b.
rhodesiense parasites when growing in human serum, as “the”
molecule conferring resistance to the non-immune lysis by NHS
(35). Using T. b. rhodesiense SRA as a fishing tool, APOL1 was
subsequently isolated from NHS and ultimately proven to be
the biochemical compound that carries the actual lytic activity
killing activity (36). Today, there is wide consensus over the
fundamentals of the APOL1-SRA interaction, the principles
that drive APOL1-mediated trypanosome killing in general,
and the way T. b. rhodesiense neutralizes the killing activity,
i.e., by capturing and degrading APOL1 during the process of
endocytosis (37). This, in turn, neutralizes the membrane pore
forming capacity that APOL1 exerts on intracellular membranes
(38). Interestingly, the way that T. b. gambiense developed
resistance against TLFs is much more complicated and appears
to combine multiple mechanisms. First, as T. b. gambiense does
not have SRA or an SRA homolog, it does not appear to have
the capacity to directly neutralize the biochemical lytic activity
of the TLFs. In contrast, the resistance mechanism of T. b.
gambiense involves (i) a reduced binding activity of TLF for
its receptor, resulting in a reduced TLF uptake, (ii) increased
cysteine protease activity involved in APOL1 breakdown, and
(iii) a role for TgsGP, a VSG-like T. b. gambiense specific
glycoprotein (39). The latter was elegantly proven by generating a
T. b. gambiense TgsGP knock-out parasite line as well as a rescue
mutant, and showing that survival in human serum directly
correlated to the presence of the targeted gene (40). Interestingly,
while these data show that T. b. gambiense went through several
evolutionary steps to become an omnipotent infective T. brucei
parasite, some primates have undergone APOL1 evolution so
that it confers resistance against T. b. gambiense. This is the
case for the West African Guinea baboon that lives in a T. b.
gambiense endemic area, and has a gene encoding for an APOL1
variant that confers protection against both T. b. brucei and
T. b gambiense (41). These examples are a clear indication of
how the arms race between parasites and host innate defense
system can shape the genome of both partners, and how even
non-immune “innate” responses can be a key factor in disease
resistance or susceptibility.
TRYPANOSOMES CONTROL THEIR
POPULATION DENSITY BY QUORUM
SENSING
The innate host immune responses obviously play a crucial role
in the control of the initial onset of trypanosome infections.
However, it is known that the peak blood parasite load in
experimental infections is not just linked to host immune factor
activity, but also depends on intrinsic characteristics of the
parasite. Indeed, early experiments using nu/nu T cell knock-
out mice, and later experiments in µMT B cell deficient mice
have indicated that maximum parasite density during peak
parasitemia is not significantly affected by either of these cell
populations and appears to be regulated by a quorum sensing
mechanism of the parasite itself. In T. brucei, this mechanism
seems to drive the differentiation from dividing slender form
parasites into non-dividing stumpy form parasites, hence halting
the proliferation of the population (42). By showing that the
system was operational in vitro, it was concluded at the time
that this sensing mechanism was independent of host factors,
and was dependent on the secretion by the parasite of an elusive
stumpy inducing factor (SIF) (43). SIF was shown to trigger cell
cycle arrest in the G1/G0 phase preceding cell differentiation,
potentially involving a cAMP signaling pathway. Without proper
identification of the exact nature of SIF, the story of quorum
sensing in trypanosomes remained silent for about 15 year,
until the recent use of a genome-wide RNAi library screen
identified the signaling components that drive stumpy formation.
Candidate genes were subsequently validated, confirming their
role in density sensing in vivo, leading to the identification of
the putative RNA-binding protein RBP7 as a key component in
both quorum sensing and cell-cycle arrest (44, 45). Interestingly,
the quorum sensing observed in T. brucei is also observed in
T. congolense although in the latter, density-dependent cell-cycle
arrest does not result in actual stumpy form formation and does
not follow exactly the same gene regulation profile (46). It does
however prepare the parasite for transmission to its definite
insect host. Under field conditions, T. brucei and T. congolense
coinfections are not uncommon, raising the question how the
quorum sensing factors of one parasite would affect the other.
The results of combined experiments showed the systems are
indeed similar as the T. congolense genes can complement the
pathway in T. brucei. In addition, conditioned culture medium
from T. congolense promotes stumpy formation of T. brucei
in vitro, and T. congolense co-infection accelerates differentiation
to stumpy forms in T. brucei (47).
Most recently, the investigation of the quorum sensing
mechanism in T. brucei has delivered an exciting breakthrough
than can explain a number of results that previously had been
difficult to align with the view that SIF is purely dependent
on the parasite, without any involvement of the host. Indeed,
while trypanosomes do not have G protein-coupled receptors
the Matthews laboratory identified a GPR89-family protein that
regulates stumpy formation in T. brucei (48). TbGPR89 is
expressed on the surface of proliferating slender form parasites
and is able to sense the presence of SIF, which so far was
only identified as a small <500 Da non-proteinaceous heat-
stable factor. Based on its structure, TbGPR89 was predicted
to be an oligopeptide transporter and given that the secretome
of T. brucei contains a number of oligopeptidases, the most
straight-forward explanation for the density-dependent stumpy
transformation is the fact that as trypanosomes accumulate in
their environment (in vitro or in vivo), so does the oligopeptidase
activity. This would subsequently create a pool of peptide
breakdown products from surrounding proteins of which specific
oligoptide compounds can be detected by the parasite. As this
signal increases, the parasite slows down its own growth, avoiding
the killing of its host by hyper parasitemia and at the same
time preparing itself for transmission to its insect vector (49).
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There are still arguments that would defend the existence of
a second density independent stumpy development pathway
in T. brucei (50), in which expression site regulation is the
key to the transformation process, but only the GPR89 driven
system would solve the question that has been raised by several
immunologists when looking at the quorum sensing mechanism
of trypanosomes, i.e., how is it possible that when comparing
parasitemia of a cloned parasite in different mice with different
genetic backgrounds, the peak parasitemia level is defined by the
genetic background of the host and not the parasite? Indeed,
when comparing the growth of identical pleomorphic T. b.
brucei AnTat 1.1E parasites in a range of different mouse strains
(including knock-out strains), peak parasitemia density directly
correlates to the intrinsic inflammatory bias of the host. Mice
with a natural low inflammatory induction potential such as
BALB/c or C3H/HeNmice show a much higher peak parasitemia
density than mice with high inflammatory induction capacity
such as CBA/Ca or C57BL/6mice (24). Also, when B cell deficient
mice on a C57BL/6 or BALB/c background are challenged
with identical T. brucei parasites, the peak parasitemia density
is very different depending on the genetic background of the
host, but not affected by the presence or absence of antibodies
(51), once again showing that the stumpy differentiation and
the control of peak parasitemia density is affected in the first
place by differences in host genetics. The answer could be that
extracellular oligopeptidases from inflammatory immune cells
and inflammation damaged tissue contributes to the formation
of the peptides that make up the SIF-pool. From an evolutionary
point of view that would mean that trypanosomes have “learned”
not just to sense their own density, but at the same time can
sense the inflammatory state of the host. When either hyper-
parasitemia, or hyper-inflammation risks killing the host, the
parasite population goes into growth arrest and counts on vector
transmission for ultimate survival.
TRYPANOSOMES AVOID
ANTIBODY-MEDIATED KILLING BY
DYNAMIC SURFACE COAT INTERACTIONS
Once trypanosomes have established a successful infection, it is
obvious that due to the extracellular nature of these infections,
antibodies are going to be the main immune component that
the parasite will have to deal with. It is generally accepted that
the pressure exerted by antibodies has resulted in the fact that
extracellular trypanosomes have developed a very sophisticated
mechanism of antigenic variation, which allows the switching
of the antigenic type of their glycoprotein coat at regular time
intervals. The mechanisms that are being used by trypanosomes
to do this are remarkably similar to the mechanism that the
host uses to generate antibody diversification (52). Indeed, while
both trypanosome “cells” and B cells use a system of mono-
allelic expression to ensure that only one VSG (trypanosomes)
or one B cell receptor (BCR) is expressed by a single cell
at any given time, both the entire trypanosome population
within the host, as well as the entire hosts’ B cell population,
both exist out of multiple different clones, representing an
overall heterogenous population. In addition, proliferation in
combination with (somatic) hyper-mutation allows both VSGs
and BCRs to play a game of hide-and-seek, ensuring chronic
infections and resulting in the continued undulating parasitemia
occurrence that is typical for natural trypanosome infection.
The occurrence of antigenic variation in human trypanosome
infections and the implications for sero-diagnostics has been
covered by others (53), and both the molecular mechanisms (54)
as well as the in vivo dynamics of antigenic variation of the
trypanosome surface coat have been described and reviewed in
detail in the past (55), and hence are not the target of this review.
Recently, the diversity of VSG genes in T. brucei was addressed
during chronic infections, using the application of long read
sequencing (56). Obtained data have confirmed the existence of
a VSG repertoire that cannot be exhausted by immune pressure,
due to the continuous generation of new mosaic genes that had
been reported earlier (57). In addition, this recent data confirms
that every parasitemia peak consists of multiple trypanosome
populations expressing multiple VSGs, that sometimes are
closely related. Finally, this data also demonstrates that there is
significant expressed diversity that follows a semi-reproducible
pattern over time, when infections in differentmice are compared
(56). Hence, in the context of this review it is interesting to
recapitulate how the antibody arm of the mammalian immune
system interacts with the trypanosome surface, and how the
trypanosome manages to evade immune destruction by the
antibody response. First, it is important to stress that for most
trypanosome species, the VSG coat consist out of a densely
packed layer of surface glycoproteins, stacking an estimated 107
identical copies of homodimer molecules evenly distributed over
the parasite surface. Hence, this coat has long been considered
as an “impenetrable” barrier. More recent structural data have
shown however that the real barrier function that would protect
the plasmamembrane is only being provided by the glycosylation
present at the base of the VSG, and that multiple invariant
surface proteins are actually fully accessible to the host antibody
response. These new data highlight the gap in our understanding
of how the VSG coat really works (58). The gap in understanding
is further highlighted by the observation that trypanosomes
that express two different VSG variants at the same time, an
event that could take place at the time point where one VSG
coat is being replaced by a new coat, fail to trigger an efficient
B cell response (59). Hence, while expressing a mosaic coat
could be a good way to evade antibody-mediated elimination,
this is not what trypanosomes have evolutionary developed as
escape strategy. Interestingly, a VSGmosaic coat does not deliver
intrinsic constraints that would hinder BCR crosslinking and
subsequent B cell activation. Indeed, it has been estimated that
the VSG density of intact T. brucei parasites is 20 times higher
than the density required for BCR cross-linking. So, even if a VSG
mosaic coat consists out of two antigenically district variants,
each of the variants should in theory be able to mediate regular
B cell activation, which is apparently not what happens (60).
Yet, experimental infections in distinct mouse strains, as well as
their F1 offspring, have shown that susceptibility to infection in
terms of limited parasitemia control and shortened survival can
be linked to the impaired capacity to mount a proper anti-VSG
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response. Interestingly, F1 generations showed that the capacity
to mount a good anti-VSG antibody response is inherited as
a dominant trait, while survival time remained similar to the
susceptible parental strain (61). These data showed that antibody-
mediated parasitemia control and disease susceptibility in terms
of survival are controlled by different mechanisms. Furthermore,
these finding were corroborated by studying T. b. rhodesiense
infections in mouse chimera models, indicating a role for IgM
in parasitemia peak control but not survival (62). With the
arrival of mouse knock-out technology, the role of antibodies in
trypanosomosis control was reassessed in various models. First,
it was shown that in experimental T. b. brucei infections, IgMs
do play a role in peak parasitemia clearance (but not the control
of the peak height itself) in the relatively virulent AnTat 1.1E
pleomorphic needle transmission model. In contrast no obvious
role was observed in the control of the low virulent TSW196
field isolate, or during tsetse fly initiated AnTat infections (51).
Interestingly, B cell deficient µMT mice (either on a susceptible
BALB/c background or a more resistance C57BL/6 background)
failed to clear peak parasitemia levels. Hence, one can conclude
that while IgMs do help to control more virulent infections,
there are other antibodies that can take over the role in parasite
clearance when IgMs are absent. In a model for T. b. rhodesiense,
it was shown that IgM antibodies have a better trypanosome
agglutination potential, but that the IgG fraction provided a
better protective response in serum transfer experiments (63).
This could be related to the better tissue penetrating capacity
of the latter, which could be important during natural and
chronic HAT infections. Next, the role of IgMs was addressed
in experimental T. congolense infections using the chronic Tc13
model. Here it was found that while C57BL/6 µMT mice were
completely susceptible and succumbed to infection following
an uncontrolled first peak of parasitemia, IgM deficient mice
survived on average nearly 4 months, similarly to the fully
immune competent controls. Interestingly, as already outlined
in the section above on innate anti-trypanosome responses,
infection control in this model was shown to be dependent on
the presence of an INFγ/NO/TNF inflammatory environment.
Most likely, this environment reduces parasite fitness, allowing
antibody-mediated clearance without the strict requirement for
the participation of IgM antibodies (23). It could be argued
however that as the T. b. brucei setting, intrinsic parasite
virulence is also a factor here and that in case of a more virulent
T. congolense infection, there could be a supporting role for
IgMs in parasite clearance. This has not been tested so far. For
experimental T. evansi infections the results appear to be the
somewhat opposite of what was reported for T. congolense. Here,
both C57BL/6 µMT mice and IgM deficient mice showed a very
high level of susceptibility, being unable to control the first peak
of parasitemia. Hence, in these infections IgGs are not able to take
over the protective role of IgM (64). Whether or not these results
were affected by the intrinsic virulence level of the stabilates used,
remains to be tested. Finally, in case of T. vivax, infections were
done in µMT mice as well as a number of cytokine deficient
mice, but not in IgM deficient mice. Results available so far show
that the combination of anti-trypanosome antibodies and an
inflammatory immune environment, in particular the presence
of TNF, is needed for proper parasitemia control, very similarly
to the results described for T. congolense (65).
So far, IgMs appear to play a crucial role in all trypanosome
models at least in the control of more acute infections. Hence,
it is interesting to speculate on the exact functional mechanisms
involved here, which could involve a role for the Fcα/µ receptor.
This Fc receptor has been shown to be important for the
endocytosis of IgM opsonized microbes (66), although it has not
been studied in the case of trypanosomosis. With no evidence for
a role of complement-mediated lysis of trypanosomes in in vivo
infection control (this is discussed in detail in the section below),
it appears indeed that phagocytosis, in particular by Kupffer
cells, of opsonized parasites is the only way that antibodies
can help in the clearance of peak parasitemia numbers (67).
Additional data suggest that the presence of an inflammatory
environment aids this process, most likely due to the fitness
reducing effects of TNF and NO, either by themselves or when
combined. Interestingly, by artificially blocking VSG synthesis
using an RNAi approach, it was shown that the process of
macrophage phagocytosis was much more efficient (68). This
finding suggests that VSG recycling is a key process in the defense
of the parasite against the attack by the mammalian antibody
response. This hypothesis is supported by an observation dating
back to 1979, when D. J. Barry first described that upon exposure
of trypanosomes to homologous antiserum, VSGs moves to the
flagellar pocket in a temperature dependent process (69). The
presence of a phospholipase C enzyme that could release soluble
VSG by cleaving its GPI anchor in the flagellar pocket, was later
suggested also to be part of the VSG-membrane recycling system
(70). The detailed recycling pathway of VSG was subsequently
described by two independent groups (71, 72), showing that
trypanosome have an extremely fast rate of endocytosis resulting
in the turnover of their VSG coat within 12min and the
formation of 6–7 clathrin-coated vesicles per second, that bud
from the flagellar pocket and deliver the membrane content to
RAB5-positive early endosomes. Next, VSG is recycled through
RAB11-positive recycling endosomes that return the VSG to the
surface. It is now believed that trypanosomes use this system
not only for the uptake of nutrients contained in the fluid phase
of the vesicles and bound to exposed membrane receptors, but
that in addition it allows the parasite to “clean” the coat from
bound antibodies. This protects the parasites from damaging
antibody functionality as long as the cells are in an optimal
metabolic state. This hypothesis was very elegantly shown by
Engstler et al. when they reported that Ig-VSG membrane
immune complexes are passively sorted to the posterior cell
pole, where they are endocytosed through the flagellar pocket.
This process requires forward cell motility and results from the
hydrodynamic forces that are encountered due to the directional
“swimming” motion of the trypanosomes (73). It was shown that
in vitro this molecular flow movement protected trypanosomes
from complement-mediated lysis. The same principle would
also protect the trypanosome from efficient antibody-mediated
phagocytosis in vivo as surface-bound antibodies would function
as molecular sails that would direct immune compromised VSGs
toward the flagellar pocket for “cleaning” or replacement (74). It
is obvious that as the immune system would mount an increasing
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antibody response with time, this systemwould become saturated
and eventually fail. However, this delay in antibody-mediated
destruction possibly offers an extended time window during
which antigenic variant can take place. This will increase the
chance that a surface VSG appears that is distinct enough to avoid
recognition of the parasite by existing circulating antibodies,
allowing the survival of some parasites within the population.
TRYPANOSOMES AVOID
ANTIBODY-MEDIATED KILLING BY
DESTRUCTION OF THE HOST B CELL
COMPARTMENT
Despite the importance of antibodies in the control of
extracellular trypanosome parasites, there is relatively little data
available describing the actual role and immunobiology of B
cells in either experimental mouse trypanosomosis or natural
human/cattle infections. In cattle, B cell responses have been
compared between trypanotolerant N’Dama and susceptible
Boran cattle, in order to try and link humoral immune response
to parasitemia control. While it has already been mentioned that
in cattle actual parasitemia control was found to be in large
regulated by the innate immune response (26), these comparative
studies did show that trypanotolerant cattle were able to produce
higher anti-VSG IgG serum responses (75). In addition, these
animals hadmore circulating lymphocytes that could be activated
in vitro to undergo differentiation into IgM- and IgG secreting
cells. In contrast, trypano- susceptible cattle showed higher
frequencies of spleen IgM secreting cells producing antibodies
that were not directed toward the trypanosome VSG coat.
Interestingly, in both T. congolense and T. vivax cattle infection,
CD5+ B1 cells were found to be the main source of poly-
reactive IgM responses, producing antibodies that bind to β-
galactosidase, ovalbumin and ferritin (76). This polyclonal B cell
activation is considered to be part of the “immunosuppression”
that characterizes trypanosome infections, as it de facto reduces
the chance for an efficient specific immune response to be
developed against crucial parasite antigens. Polyclonal B cell
activation has also been reported in experimental infections with
T. b. brucei and T. b. rhodesiense in mice (77). While the latter
report linked this immunological phenomenon to the presence
of the VSG, the exact mechanism driving the activation has so
far not been unraveled. Besides polyclonal activation, there are
two other B cell biology observations that merit attention in the
context this review, i.e., the non-classic regulation of Ig class
switching, and the destruction of the B cells compartment that
constitutes the main pathology problem for the immune system
during chronic infections. Unusual Ig class switching was first
described in a study that measured anti-VSG isotype profiles
during T. b. rhodesiense infections in mice. Here is was found
that both fully immune competent C57BL/6 mice as well as T cell
deficient nu/nu mice were able to mount a very similar switched
anti-VSG response that mainly consisted out of IgG1, IgG2a, and
IgG3 antibodies. This occurred in the presence of IFNγ and IL-2,
but the absence of IL-4 and IL-5. However, when repeating these
measurements in IL-4 knock-out mice, a significant decrease in
IgG1 titers was observed, indicating a role for this cytokine in
the regulation of B cell activity, independent of antigen specific
Th1 or Th2 cells (78). In the same context, IgG switching was
also observed in experimental T brucei infections in bothWT and
nu/nu BALB/c mice, with IgG1, IgG2a, IgG2b, and IgG3 isotype
antibodies being produced independent of conventional T cell
help (79). Interestingly, in both models the lack of T cell help did
not seem to hamper parasitemia control, while the lack of Il-4 and
the subsequent capacity to drive an IgG1 B cell differentiation
pathway also did not affect parasitemia control. One example
where B cell regulation was shown to be a crucial arm of
parasitemia control was in chronic T. congolense infections in
mice. Here Bam32, responsible for downstream signaling linked
to BCR crosslinking, was shown to be crucial for prolonged
parasitemia control, albeit redundant for early peak parasitemia
elimination (80). This observation aligns with the finding that T.
congolense infections cause a sustained disruption of the B cell
homeostasis in bone marrow and spleen, and that the virulence
index of different stocks in experimental mousemodels correlates
with the potential to drive B cell destruction (81). When it comes
to immune destruction of the B cell compartment, this has also
been documented in detail for T. vivax (82) and in more detail
for T. brucei (83). In the latter model it has been shown that the
early loss of B cells is linked to an excessive inflammatory IFNγ
response (84), can involve the NK cell mediated killing activity
(85), is observed both at the level of the bone marrow and spleen
(86) and takes several weeks to be restored after drug treatment of
experimentally infected mice (87). Also here, infection-induced
B cell destruction seems to be associated to parasite virulence as
mice that are infected with very chronic T. b. gambiense parasites
do not seem to suffer the same B cell depletion problem as those
infected with a much more acute T. b. brucei strain (88).
SERUM COMPLEMENT FACTORS
MEDIATE PARASITEMIA CONTROL IN
VIVO, BUT NOT TRYPANOLYSIS
Immunoglobulins only have a limited range of function they can
perform by themselves. In essence, good antibodies are proteins
that bind their target with high affinity and specificity. For
trypanosomosis control, both antibody-mediated phagocytosis
(discussed above) and antibody-mediated complement lysis
are quoted throughout the literature. However, four decades
of complement research in the context of trypanosomosis
have shown that “lysis” is not the mechanism that mediates
parasitemia control during in vivo infection. The reason for the
persistence of this misconception about complement lysis of
trypanosomes has probably to be attributed to the fact that in
vitro antibody-mediated trypanolysis assays are being used as
diagnostic tools for the detection of active infections. Indeed,
when cultured or purified trypanosomes are incubated in vitro
with high amounts of complement-rich guinea pig serum and
plasma from infected individuals or animals, trypanosomes
tend to lyse over time proportionate to the amount of anti-
trypanosome antibodies present in the donor serum (89). This
phenomenon has been very clearly described in the 1970’s in
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the correct context of the particular in vitro conditions for
T. congolense and T. brucei, and the authors also immediately
discussed the limitations of the observation with respect to the
in vivo situation (90). Also the involvement of the alternative
activation of the complete cascade under in vitro conditions with
the role of C3 and the formation of covalently immune complexes
between released soluble sVSG and C3b has been described,
without any claim that this would represent the system that
controls parasitemia in vivo (91). In fact, over the years, a wealth
of data has been published that shows that parasitemia control
in vivo occurs totally independent from the lytic complement
cascade, and that trypanosomes have a number of tools at
their disposition to efficiently prevent complement-mediated
lysis of actively dividing bloodstream form parasites. Maybe the
most compelling data in this context comes from experimental
infections in animals that simply do not have the capacity to
activate the full complement cascade due to genetic mutations.
For example, AKR mice as well as B10.D2/oSnJ mice are both
deficient for C5. Hence, while the complement cascade can be
initiated in these mice with the formation of the opsonin C3b
molecule, the cascade cannot progress toward the formation of
the membrane pore forming 10–16 C9 complex. Therefore, the
fact that B10.D2/oSnJ mice are able to control successive waves
of T. b. rhodesiense infection proves that complement-mediated
lysis is not crucial in the process of either peak parasitemia
control, or peak parasitemia clearance (92). Similarly, these C5-
deficient mice were capable of controlling T. musculi infections
(93), as well as T. congolense infections (94). Also AKR mice
were used to study the progression of infection in models for
both T. b. rhodesiense (95) and T. vivax (65), showing again that
peak parasitemia control as well as peak parasitemia clearance
occurs in the absence of C5, and by consequence in the absence of
complement-mediated trypanolysis. The lack of C5 involvement
in trypanosomosis control is further corroborated by the fact
that T. congolense infections hardly affected plasma C5 levels in
a range of different mouse models, including highly susceptible
and highly tolerant strains (96). Interestingly, the latter study did
report that trypanosome infections resulted in a rapid decline of
C3 in all strains tested. This confirmed earlier results that had
shown that while C8 levels are unaffected during infection C1,
C1q, and C3 levels all decrease in plasma of T. congolense infected
cattle (97) as well as in T. vivax infected cattle (98). Finally, it
is important that these experimental mouse and cattle data also
reflect the situation in humans. Indeed, while T. b. gambiense
does activate C3 and binds C3b on its surface when incubated
with human serum, it does not result in the formation of C5 or the
polymerization of C9. Hence, trypanosomes are not lysed as the
complement cascade does not continue beyond the establishment
of C3 convertase (99).
So, could there still be a role for complement in the
control of trypanosomosis? The “yes” answer relates to the
fact that besides lysis, the initial stages of complement are
crucial for the generation of the C3b component, a powerful
opsonin that binds covalently to its target (100). By interaction
with plasma Factor H and I, C3b can be converted into
iC3bi (or C3bi) which is a target for the CR3 (CD11b/CD18)
receptor involved in pathogen phagocytosis (101). In case of
T. congolense infections it has been described that mice with
effective prolonged parasitemia control and low parasitemia
peaks (C57BL/6) have a faster and greater C3b production
than mice that intrinsically fail to control the infection with
the first 2 weeks of a parasite challenge (BALB/c) (102). This
activity correlates with the finding that the CR3 receptor is
a major player in the endocytosis of T. congolense parasites
after opsonization of the parasite by IgM antibodies (103).
Interestingly in an innate immune context is the finding
that CR3-mediated phagocytosis is also directly linked to
macrophage TNF production, an inflammatory cytokine that as
described above has a profound negative impact on trypanosome
fitness. Complement associated phagocytosis has also been
described for T. brucei (104), and more recently the use
of C3 knock-out mice confirmed a role for complement in
peak parasitemia clearance during T. brucei infections (85).
All these data confirm older results showing (i) that early
stage complement cascade activation is important for parasite
clearance (105), (ii) that hepatic phagocytosis of trypanosomes
depends on the presence of C3, and (iii) that in vivo, no
intravascular lysis of parasites is observed during events of
immune clearance (106). However, simply to illustrate the
complexity of the immune system, it should be said that in the
presence of IgM opsonization of T. brucei parasites, treatment
of mice with CVF (cobra venom factor) that neutralizes C3,
did not ablate the capacity of macrophages to phagocytose
trypanosomes. This shows that in immune competent mammals,
multiple mechanism are in place to deal with peak parasitemia
clearance (107).
Taken that C3b/iC3b deposition on the VSG surface coat
can result in hepatic phagocytosis, the trypanosome must
have defense mechanisms in place in order to ensure that
this system does not lead to population elimination. As
already outlined above, rapid VSG circulation comes into
play here, as a defense system against any host compound
binding to the surface (108) and as a tool for complement
surface clearance in particular (109). Secondly, the densely
packed nature of the VSG coat itself offers physical protection
against any possible complement-mediated lysis (110). Finally,
it has been proposed that trypanosomes have two more
defense systems in place that could help the fight against host
complement. First, trypanosomes were shown to express a
homolog of the Leishmania GP63 surface protease that has
been shown to confer resistance to complement-mediated
lysis (111). Secondly, T. brucei was shown to bind human
complement regulatory protein C4BP. Acquisition of this
factor on the surface of pathogens is correlated to the
downregulation of complement activation (112). Hence,
together these mechanisms provide the trypanosome with
adequate tools to confer resistance to complement mediate
lysis, but at the same time allow the immune system to
clear parasites trough phagocytosis in the liver. The latter
would be particularly helpful when parasite fitness is reduced
due to ongoing inflammatory responses triggered by the
innate immune system, and during events of parasite growth
inhibition that result from the quorum sensing mechanisms
described above.
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T CELLS CONTRIBUTE TO THE
MAINTENANCE OF AN
ANTI-TRYPANOSOME INNATE
INFLAMMATORY ENVIRONMENT
Since the very beginning of trypanosome immunology research,
T cells have been considered crucial for proper trypanosomosis
control. How and why this is the case, strongly depends on
the model studied and the definition of infection control. For
example, when calves were depleted from CD4+ T cells and
trypanosome control was studied, the effects observed were
strongly dependent on the intrinsic trypanotolerance of the
breed. While T cell depletion always had a very severe negative
effect on antibody production, this did not impact parasitemia
control in trypanotolerant N’Dama cattle. In contrast, the same
treatment had a profound negative impact on parasitemia control
in susceptible Boran cattle (26). This finding suggests that while
T cell mediated responses can help to bring parasitemia under
control in certain conditions, there are T cell independent
factors that can be responsible for intrinsic trypanotolerance.
CD8+ T cell depletion in susceptible Boran cattle did not affect
parasitemia control (113). N’Dama/Boran chimera experiments
in cows confirmed that intrinsic parasitemia control was
controlled by a hematopoietic independent mechanism, while
disease control, i.e., anemia development, was in contrast
dependent upon the hematopoietic system.
In mice, control of trypanosome infectious does not exactly
mirror the observations of cattle, but there are parallels. A
first interesting observation is the T cell deficient nu/nu mice
on either BALB/c or C57BL/6 background have no problems
in controlling parasitemia in comparison to fully immune
competent mice (51, 79). In fact, when it comes to pathology
control, C57BL/6 mice that lack T cell altogether, or just CD8+
T cells, suffer less from infection-associated anemia (9), and
have a prolonged lifespan in case of nu/nu mice when infected
with T. b brucei or T. b. rhodesiense (9, 114). This dichotomy
between parasitemia control and pathology/survival most likely
reflects the complex role T cells play in (i) sustaining the
innate inflammatory environment needed for proper parasitemia
control, (ii) the immunopathology associated with prolonged
inflammation, and (iii) in case of CD4+ T cells, their role in
helping a T cell dependent anti-trypanosome antibody response.
As also discussed above, antibodies involved in trypanosomosis
control in mice comprise both a T cell independent and T cell
dependent fraction. Indeed, while even nu/nu mice are able to
raise VSG specific antibody responses, fully immune competent
mice often—but not always—show a better response (115).
Interestingly, in fully immune competent mice T cell responses
to trypanosome VSG are not limited to the hypervariable regions
but also cover the less variable regions of the N-terminal domain
that are inaccessible for antibodies. At the same time however, it
appears that during experimental infections no T cell are raised
against epitopes located in the relatively invariant C-terminal
part of the VSG (116). This opens an interesting hypothesis for
future vaccine attempts which is also discussed further in this
paper: could it be that trypanosomes evolved to have an immune
evasion mechanism that prevents exposing conserved epitopes in
an MHCII context, so that during infection no T cell memory
is developed against such structurally important domains? While
these domains are constrained with respect to sequence variation
due to their functional importance for VSG structure, they
are buried at the base of the VSG and hence are relatively
safe from antibody recognition. If, however such epitopes were
to successfully recognize by the T cell immune compartment
after antigen processing, they could serve according to the
hapten-carrier concept as CD4+ T helper cell generators that
would provide help to all anti-VSG B cells, against all surface
exposed epitopes. This would negatively affect the fitness of
the trypanosome. Hence, while such negative selective pressure
would favor the acquisition of non-immunogenic conserved
regions, the artificial induction of T cell responses against these
epitopes prior to infection might tip the balance in favor of the
host, in a way that trypanosomes have not been evolutionary
prepared for (4).
Beside the possible help to B cells, it is clear that T cells
provide crucial help to the maintenance of a correct cytokine
environment, needed to help control parasitemia through innate
related mechanisms. Indeed, it has been shown that in C57BL/6
mice that exhibit a relatively good parasitemia control, infection
control is associated with the induction of Th1 CD4+ responses,
characterized by the production of IFNγ and IL-2 and the absence
of IL-4 (117). The importance of this response for macrophage
activation and parasitemia control was confirmed by the fact
that C57Bl/6 IFNγ knock-out mice are highly susceptible for
trypanosome infections, as already indicated in the section that
covered the innate protection against the parasite. In contrast,
IL-4 knock-out mice showed a phenotype that was identical
to fully immune competent mice (7). This drive toward Th1
differentiation has been correlated directly to the splenic DC
antigen presentation of VSG that coincides with IL-12 secretion
(118). At first, these results might seem conflicting to the
results observed in trypanosome infected nu/nu mice, where the
latter are characterized by a normal parasitemia control. It is
however important to emphasize the fact that infection-induced
IFNγ production does not solely result from the presence
of activated CD4+ T helper cells. In particular during early
infection, it was indeed shown that the first cells to respond
with a significant IFNγ secretion are NK cells, subsequently
followed by NKT cells and only later by Th1 CD4+ T cells
and CD8+ T cells. Hence, it is possible that as far as the early
need for IFNγ is concerned, nu/nu mice have a compensatory
mechanism in which the NK/NKT compartment delivers the
correct cytokine environment to control early parasitemia by a
combination of inflammatory cytokines and T cell independent
antibodies (9). Finally, one line of thinking that also could
explain in part the results observed in overall comparative mouse
infection, is that so called “wild type” mice undergo an immune
suppression of T cells that makes them de facto closely resemble
functional T cell deficient mice. In this case, trypanosome
infected WT mice would indeed functionally resemble nu/nu
mice in some respects, despite the presence of T cells in the
lymphoid circulation.
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TABLE 1 | Summary of vaccine candidates reported in literature.
Type of
vaccine
Antigen Antigen
preparation
Boosts/host Time gap
boost-challenge
Parasite load Outcome References
Intra-muscular T. b. rhodesiense FP Parasite isolated 3/cattle 14 days or more Natural exposure Partial protection (120)
I.p. T. b. brucei AnTaR FP Parasite isolated 3/mouse (Balb/c) 3 weeks 500–103 Partial/no
protection
(121)
I.p. T. b. brucei MITat
ISG65, ISG75
Recombinant
protein
3/mouse (C57bl/6) 11 days 104 No protection (122)
I.p. T. b. brucei ISG75 Plasmid DNA 1/mouse (Balb/c) 175 days 500 Partial protection (123)
I.p. T. b. brucei
GuTat10.0 Ca2+
ATPase TBCA2
Recombinant
protein
3/mouse (Balb/c) 6 weeks 106 No protection (124)
Sub-cutaneous T. brucei
(UTRO010291B)
Tubulin rich fraction
Parasite isolated 3/mouse (no strain
indication)
Not indicated 103-105 Partial
(cross-species)
protection
(125)
Sub-cutaneous T. evansi (STIB806)
b-Tubulin
Recombinant
protein
3/mouse (Balb/c) 6 days 103 Partial
(cross-species)
protection
(126)
Intra-muscular T. evansi (EU483116)
β-Tubulin
Plasmid DNA 2/mouse (Swiss
albino)
35 days 103 No protection (127)
Sub-cutaneous T. evansi (EU483116)
β-Tubulin
Recombinant
protein
2/mouse (Swiss
albino)
14 days 103 No protection (128)
Sub-cutaneous T. evansi (STIB806)
Actin
Recombinant
protein
3/mouse (Balb/c) 6 days 103 Partial
(cross-species)
protection
(129)
Sub-cutaneous T. congolense CP1 &
CP2
Recombinant
protein
4/cattle (Boran) 1 month Tsetse bite Improved recovery (130)
Intra-muscular T. b. brucei Sialidase Plasmid DNA 1/mouse (Balb/c) 175 days 500 Partial protection (131)
I.p. T. congolense
Sialidase
Recombinant
protein
4/mouse (Balb/c) 10–14 days 104 Partial protection (132)
I.p. T. b. brucei AnTat GPI GPI-Liposomes 2/mice (C57bl/6
and KOs)
3 weeks 5 × 103 Cross-species
anti-pathology
(133)
I.p., intraperitoneal; FP, Flagellar Pocket; ISG, Invariant Surface Glycoprotein; GPI, glycosylphosphatidylinositol; CP, Cystein proease.
EXPERIMENTAL ANTI-TRYPANOSOME
VACCINES HAVE SO FAR NOT BEEN
TRANSLATED INTO APPLICABLE
VACCINES
In 2011, we published a comprehensive overview of anti-
trypanosome vaccine data that was available at the time (119).We
concluded that while there is a fair amount of “promising” results
in the literature, there is little prospect of seeing a successful
field applicable vaccine any time soon. Ten years later, a number
of additional results have been published, but it appears that
the latter statement still stands. An overview of the currently
reported anti-trypanosome vaccine data is provided in Table 1.
The rationale behind most anti-trypanosome vaccine efforts is
to vaccinate a host with invariant trypanosome proteins or a mix
of such targets. Given the role of the flagellar pocket in nutrient
uptake, and the presence of a number of surface receptors
and invariant surface molecules such as the LDL receptor and
the HpHb receptor, Invariant Surface Glycoproteins ISG65 and
ISG75, and SRA (134), the FP was targeted in two independent
approaches. In one report, cattle were inoculated with crude
antigen extracts derived from the FP of T. b. rhodesiense, and
subsequently exposed through a possible natural challenge with
T. congolense or T. vivax by releasing the animals in their
natural field habitat (120). This resulted in a significant drop in
infection prevalence at the end of the observation period that
lasted 15 months. In a more controlled mouse vaccine study, FP
vaccination was conducted using highly purified material from
T. b. brucei parasites. Borderline protection was observed when
mice were challenged with 500 live bloodstream form parasites,
with 60% of mice not developing parasitemia for a period of up
to 100 days (121). No protection was observed however when
mice were challenged with 1,000 parasites or more. Important
is that the ultimate idea behind a vaccine is to deliver memory
recall responses for prolonged periods of time. In the setting
used here, this was not tested as the waiting period between the
last boost and the parasite challenge was only 21 days. Hence,
immunemodulation events, including innate responses triggered
by repeated adjuvant exposure, could have contributed to the
limited protection observed here in a low-dose challenge setting.
Upon discovery of the invariant trypanosome surface proteins
ISG65 and ISG75, they were considered as viable vaccine
candidates. While ISG75 was shown to be a good antibody
inducer, no protection was observed in a vaccine setting using
a homologous parasite challenge, despite the very short 11-day
waiting period between the last boost and the actual parasite
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injection (122). Next, a DNA vaccine approach targeting ISG75
was tested. Here, a single vaccination was followed 175 days
later by exposure to a low-dose challenge with 500 T. b brucei
GVR35 parasites. The results obtained were virtually identical
to the mouse FP vaccine low-dose challenge experiment and
showed 60% protection against parasitemia for a period of
at least 60 days (123). As in the case of the FP vaccination,
this outcome was associated with a strong IgG2a antibody
presence, indicative of an IFNγ driven cytokine environment.
These results do not conclusively point to the involvement of
an antibody effector mechanism and could equally well-indicate
that biasing the host toward a strong inflammatory mediated
immune regulatory environment, favors protection against low-
dose parasite exposure, due to a more efficient help to the innate
anti-trypanosome immune response. A very similar conclusion
can be made for an anti-trypanosome vaccination that used
the Ca2+ ATPase TBCA2 antigen as a target in BALB/c mice.
This trypanosome membrane pump was formulated in a Vibrio
cholera ghost-based vaccine, after it was identified as one of
the conserved FP components (124). This vaccine gave rise
to the induction of a prominent IgG2a response accompanied
by a strong IFNγ cytokine production. However, in this case
the combination of these favorable factors did not prevent the
successful onset of parasitemia by T. brucei trypanosomes, as
the infection was initiated with an extremely high number of
106 parasites.
By far the most often targeted trypanosome antigen is the
tubulin protein, and as a variation on the idea, the actin
protein (125–129, 135). Both proteins are part of the intracellular
cytoskeleton structure and have functions in motility and
intracellular organelle transport but are not accessible by the
host antibody response. This makes the repeated reports of the
successful induction of protection using various protocols very
interesting. What all the protocols have in common, is that the
waiting period between the last boost and the actual challenge was
too short to asses vaccine induced memory, in some cases being
limited to 6 days only. Hence, these protocols again assessed the
direct effect of immune modulation by the procedure. What all
reports also have in common is that none of them attempted to
explain how the intracellular trypanosome proteins would have
been targeted by the host antibody response in order to provide
sterile protection. Once again, the most obvious explanation is
that the applied protocol provided an improved inflammatory
environment that favored the innate immune control of infection
during the onset of parasitemia.
So far, most anti-trypanosome vaccine studied have been
performed in mice, for obviously logistical reasons. Several
authors have however questioned this approach and have
argued that vaccine studies for AT should be conducted in
the relevant host. The only molecular target that has been
tested in this context is the T. congolense cysteine protease
congopain, after it was shown that trypanotolerant N’Dama
cattle, but not trypanosusceptible Boran cattle, mount and IgG1
response against this target (136). Successfully vaccinated cattle
did show increased anti-CP serum antibody titers, as well
as anti-VSG titers, coinciding with improved in parasitemia
control (130). Next, the immunogenicity of CP was improved by
coupling the catalytic domain of the enzyme to α2-macroglobulin
(137), and various adjuvants were compared leading to the
adjuvant choice of Quil ATM for future experiments (138).
Important to stress here is that this approach is not an anti-
parasite approach, but in the end, it is a way to modulate
the host immune response and alleviate the inflammatory-
associated immune pathology of trypanosomosis. The molecular
mechanism by which this was achieved still remains open
for discussion.
Using trypanosome enzymes as vaccine targets has also
been applied in a T. brucei setting, targeting trans-sialidase
(TS). Using TS encoding plasmid DNA, a single-dose vaccine
experiment was followed 175 days later by a T. b. brucei GVR35
challenge, using 500 parasites. The obtained results show a
40% protection against infection for a period of at least 60
days (132). As the report did not detail a functional antibody
analysis, it is difficult to provide a final mechanistic hypothesis
for the partial protection. However, given the type of vaccine
used (DNA vaccination) one could once again suggest that an
IFNγ-driven helper response could be part of the equation,
helping both the innate response immediately upon parasite
challenge, as well as the IgG2a response that would occur upon
B cell reactivation. In a follow-up vaccination approach against
T. congolense, this time using recombinant TcoTS, protection
levels reached 15–40% (131). Here, vaccine-induced memory
responses were once again not addressed as the waiting period
between the last boost and parasite challenged were limited to
<14 days. Hence, this makes it very plausible that the limited
level of protection observed was related in part to immune
modulation and improved innate responses, rather than just
anti-trypanosome antibody induction.
By considering the strategy of anti-pathology vaccination,
rather than anti-trypanosome vaccination, our group has
taken a radically different approach in the past to find new
ways of dealing with the problems of trypanosomosis. After
having identified the VSG-GPI anchor as the main driver
of inflammatory pathology and macrophage-derived TNF
production (13), we approached anti-disease vaccination
for T. b. brucei, T. evansi, and T. congolense by using a
liposome-based GPI vaccine. By challenging mice several
times with GPI liposomes prior to trypanosome exposure,
the infection-associated pathology was reduced and the
lifespan of infected mice was significantly increased (133).
Interestingly, using B-cell deficient mice, we were able to
show that the observed effect was totally independent of
antibody function, even though the protocol did result
in the successful induction of antibodies in WT animals.
These experiments conclusively showed that vaccine induced
immune modulation of inflammation was at the core of the
protection. The observation that the CD1d molecule was
crucial for mediation of the observed protection, indicates
a major role for the modulation of the innate immune
system (133).
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TABLE 2 | Summary of the detrimental effect of trypanosomosis in non-related vaccines, B cells, and B cell malignancies.
Parasite Host Disease/vaccine Readout Outcome Functional
readout
References
T. brucei Mouse Bordetella pertussis CFU counts Increased lung
CFUs
Loss of vaccine
protection
(82)
T. b. gambiense Human HIV Ab titers Diagnostic test Decrease in
specificity
NA (139)
T. b. gambiense Human Measles Ab titers Diagnostic test Decreased titers NA (140)
T. congolense/T. vivax Cattle CBPP Ab titers/experimental
infection
Decreased titers 50% susceptibility (141)
T. congolense/T. vivax Cattle/mice Louping-ill virus Ab titers 90% titer reduction NA (142)
T. congolense Cattle Foot-and-mouth virus Ab titer Decreased titers Virus challenge/no
effect on protection
(143)
T. congolense/T. vivax Cattle Brucella abortus Ab titers 80–90% titer
reduction (T.
congolense)
NA (144)
T. evansi Buffalo Pastuerella multocida Ab titers/inflammation Decreased titers NA (145)
T. evansi Buffalo Pasteurella multocida Ab titers/lymphocyte
proliferation
Decreased titers
immuno-
suppression
NA (146)
T. evansi Pig Classic Swine Fever
(CSF)
Ab titer/fever Decreased titers Decreased fever (147)
T. brucei Mouse Trichinella spiralis Ab titers/eosinophil
counts lymphocyte
proliferation
Decreased titers
immuno-
suppression
Decreased worm
expulsion
(148)
T. brucei Mouse T. brucei/homo-
heterologous
Parasite count Short-lived specific
protection
Loss of short-lived
protection
(82)
NA, None applicable.
TRYPANOSOME INFECTIONS ABLATE THE
EFFICACY OF NON-RELATED
PROTECTIVE VACCINES
To date, it seems there no data is available that suggests that
vaccine induced immunological memory can be recalled upon
during ongoing trypanosome infections, in order to help the
host to recover from infection. In addition, combined data
shows that infection-associated inflammation is detrimental for
the host immune system as whole, and as such could affect
immune responses against non-related co-infections, or non-
related vaccines. In recent years, this question has been addressed
using both experimental mouse models and human case studies.
In the past however, a significant amount of data has already
been published indicating that trypanosomes do compromise the
host immune system of natural hosts in general. In addition,
there is data available showing that HAT and AT affect antibody
titers against non-related disease, which is particularly important
when considering antibody-based diagnostic test evaluation in
trypanosomosis endemic areas. All these observations have been
summarized in Table 2.
The first time that the detrimental effect of experimental
mouse trypanosomosis was investigated in detail in a
heterologous vaccine setting, was by analyzing the effect of
T. b. brucei infections on the efficacy of the commercially
available DTPa vaccine (Boostrix R©), which provides protection
against diphtheria, tetanus, and whopping caught infections
(83). After having observed a complete and permanent ablation
of vaccine-mediated protection by the trypanosome, it was
proposed that it should be assessed whether such immune
destructive effect could threaten vaccine efficacy in humans.
While experimental pathogen re-challenge experiments in
humans can obviously not be performed in a HAT setting, two
follow-up observations are worth mentioning in this context.
First, it was shown that T. b. gambiense infections decrease
the specificity of antibody detection tests for HIV diagnosis,
warning that classic algorithms that are being used for test
interpretation on non-HAT individuals, might not be able to
provide adequate diagnostic answers in HAT patients, even after
treatment (139). Next, it was shown that HAT patients who had
been vaccinated against measles had significantly lower antibody
serum titers compared to non-HAT individuals. Antibody titers
remained low after curative anti-HAT treatment, although they
were above the guideline cut-off in healthy individuals (140).
However, as was the case for the HIV diagnostics, the measured
antibody levels could very well be an over estimation of the
actual functional titer. This is also what has been observed
in the case of contagious bovine pleuropneumonia (CBPP)
vaccinations in cattle. Here it was shown that in T. congolense
infected animals, a vaccine against CBPP lost 50% of its efficacy,
while only a minor drop in antibody titers was observed (141).
Such drop in non-trypanosome related vaccine efficacy, due to
the presence of animal trypanosomosis, has been observed in
models for louping-ill virus protection (142), foot-and-mouth
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FIGURE 1 | Overview of the crucial aspects of trypanosome-host interactions. Upon infection, trypanosomes are confronted with an early stage inflammatory immune
response in which IFNγ is being produced by NK, NKT and subsequently CD4+ T cells. This drives the activation of macrophages which in term respond to parasite
secreted and released factors, including shedded VSG (Variant Surface Glycoprotein). Activated macrophages produce TNF and Nitric Oxide (NO) that negatively
impact on parasite fitness. Antibodies, derived first through T cell independent B cell activation and later through T cell dependent activation, will attack the surface of
the trypanosome. Deposition of the C3b complement will also occur. Together, these immune molecules will help in controlling parasitemia, but trypanosomes
themselves have defense mechanisms that will help survival. Through lateral VSG movement to the flagellar pocket (FP) antibodies and complement factors are
cleared, limiting damage. In order to prevent early killing of the host through parasite overpopulation, trypanosomes have developed quorum sensing, which results in
density dependent growth arrest and preparation for vector transmission. Combined, this innate control of infection results in prolonged inflammation with a
detrimental outcome for the adaptive immune response. Late stage infections are characterized by B cell destruction, T cell mediated immune suppression, loss of B
cell memory recall capacity and irrelevant polyclonal B cell activation.
vaccination (143), a cattle vaccine model for Brucella abortus
(144), immunization against Pasteurella multocida (145, 146),
classic swine fever (CSF) vaccination (147), and in a vaccine
setting for Trichinella spiralis (148). Finally, staying within
the boundaries of the trypanosome mouse model, we assessed
functional anti-VSG memory responses. Here we used a live
infection model rather than a vaccine model in which mice
were first challenged with low-virulent parasite clone, followed
by a secondary infection with a high virulent clone expressing
either an identical VSG surface coat is the parasite used in the
primary infection (homologous challenge) or a different VSG
coat (heterologous challenge). The obtained result showed that
while the first infection did provide VSG-specific protection
against a homologs challenge, the protection was short-lived
and disappeared within 10 days after clearance of the first
wave of the primary infection. Using B cell knock-out mice,
we showed the temporary protective response relied on T-cell
independent antibodies (82). However, by using a battery of
cytokine deficient mice including TNF and IFNγ knock-out
mice it was obvious that the short-lived protective antibody
response only works in an inflammatory environment that is
driven by the early innate immune response. This can explain
the abolishment of the protection by day 17 post infection,
despite the presence of high anti-VSG antibody titers at the time
of challenge.
CONCLUSIONS
Extracellular trypanosomes are very successful parasites that
today are still expanding their territory. While the terminology
“African trypanosomes” is often used synonymously for
salivarian trypanosomes, it should be remembered that T. evansi
was the first extracellular trypanosomes to be discovered, and
that this discovery was made in India. Hence, the presence of
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these parasites should be considered as a global issue, with a
possibility of affecting all commercially important livestock
mammals as well as game animals. Due to their extracellular
nature, and their continuous confrontation by the mammalian
immune system, trypanosomes had to acquire multiple defense
mechanisms to overcome mainly the dangers posed by host
antibodies (Figure 1). Coating their extracellular membrane
with a dense layer of VSG glycoproteins offers protection against
antibodies, but most likely not in ways that have been suggested
in the early days of trypanosome research. First, when during
infection the host manages to mount an anti-VSG response,
binding immunoglobulins function as molecular sails, and
complexed membrane VSG molecules are rapidly transported
to the flagellar pocket where they are endocytosed, cleaned and
recycled or replaced. Having a de facto unlimited library of
VSG genes, pseudogenes and the capacity of generating mosaic
genes, allows the parasite to switch the antigenic type of the
coat and hence avoid complete elimination of the population.
Combining this mechanism with the destruction of the host B
cell compartment allows the trypanosome to outrun the dangers
posed by the host humoral immune response. In addition,
multiple studies using mouse knock-out technology, natural
mutant mouse strains and AT as well as HAT observations
have shown that complement-mediated lysis cannot be used as
part of the host defense system, as the complement cascade is
blocked from forming C5–C9 components needed for actual
lysis. This leaves the host with the system of iC3b-mediated
phagocytosis, mainly performed by inflammation-activated
Kuppfer cells. In order to protect itself from phagocytosis,
the parasite once again uses VSG recycling to prevent total
population elimination by clearing iC3b surface deposition.
Important however in the case of a parasite, is the fact that killing
the host is not a good survival strategy. Hence, trypanosomes
have developed a system of quorum sensing that allows them
to regulate proliferation in response to parasite density, and
most likely is also capable of sensing excessive infection-
associated inflammatory tissue damage. While this is crucial
to ensure prolonged host survival, it does not prevent the
infection of leading to the virtually complete destruction of
the host B cell compartment. The latter is most likely the
reason for the fact that so far not a single promising laboratory
vaccine has been translated into a useful field application. In
addition, it explains why many commercial vaccines against
unrelated diseases appear to lack efficacy in trypanosome
endemic areas. The latter is the case for trypanosusceptible
animals, and this could be the foundation for the distinction
between susceptibility and tolerance for infection. While
trypanotolerance has been described in detail for particular
cattle breeds, it is only recently that this phenomenon has now
been suggested to also occur in some humans. It would be
interesting to see in the future how the B cell compartment
of such individuals behaves, as compared to the bulk of the
human population that is considered trypanosusceptible.
Subsequently, it could be assessed in a HAT context how the
relative importance of the innate immune system and the
adaptive immune system compare to each other, both in the
control of onset of infection as well as in the control of the
chronic infection stage.
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